Gilead Offers Voluntary Licenses for Manufacturing of Viread in Developing World

Gilead is offering non-exclusive, voluntary licenses to generic manufacturers in India for the local Indian market as well as provision for manufacturers to export product to the 97 developing world countries included in Gilead’s access program. We are in discussions with a number of interested parties and welcome requests from others. We will provide more details as these agreements are finalized. We believe that multiple manufacturers will ensure competitive prices and the broadest access possible in these least developed countries.

Gilead filed a patent application for Viread® (tenofovir disoproxil fumarate) in India, and we expect this patent to issue shortly. We disagree with statements that Viread should not be patented; we believe that Viread represents innovation and is patentable under Indian law. We will use this patent responsibly, and will not block access to our medication in India or in other resource-limited countries where the HIV epidemic has hit the hardest.

We remain committed to completing registrational filings in all countries of the company’s access program. Applications in 61 countries have been completed, and the remaining filings will be submitted before year end.